Rapport Therapeutics (NASDAQ:RAPP) Stock: Insider Steven Paul Buys 35,714 Shares

Key Points

• Director Steven Paul bought 35,714 shares of Rapport Therapeutics at an average $27.28 per share, investing approximately $974,278 and increasing his ownership by 85.71% to 77,380 shares.
• Rapport’s lead drug candidate, RAP-219, met both Phase 2 endpoints in bipolar mania and is advancing to Phase 3, prompting several analysts to maintain Buy ratings or raise price targets.
• The company remains an unprofitable clinical-stage biotech, with its latest quarterly EPS missing expectations and continued risks tied to clinical execution, regulatory approval, funding, and commercialization.

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) Director Steven Paul purchased 35,714 shares of the company's stock in a transaction dated Thursday, October 22nd. The stock was purchased at an average price of $27.28 per share, for a total transaction of $974,277.92. Following the completion of the purchase, the director owned 77,380 shares in the company, valued at approximately $2,110,926.40. The trade was a 85.71% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Rapport Therapeutics Price Performance

Rapport Therapeutics stock traded up $1.47 during mid-day trading on Thursday, reaching $26.53. 1,453,606 shares of the stock traded hands, compared to its average volume of 407,078. The stock has a market capitalization of $1.27 billion, a PE ratio of -8.73 and a beta of 1.22. Rapport Therapeutics, Inc. has a 12-month low of $23.75 and a 12-month high of $52.93. The business's 50-day moving average is $39.86 and its 200-day moving average is $39.07.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.07). Equities analysts anticipate that Rapport Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.

Rapport Therapeutics News Summary

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 is advancing to Phase 3. Rapport said the drug met both Phase 2 endpoints in bipolar mania, producing statistically significant placebo-adjusted improvements in manic symptoms and overall illness severity. The results strengthen the potential value of RAP-219 and expand its development opportunity beyond epilepsy. Rapport plans Phase III bipolar mania trials
• Positive Sentiment: Analysts continue to raise or maintain bullish targets. JonesTrading increased its price target from $50 to $82 and maintained a Buy rating. BTIG Research also raised its target, while HC Wainwright reaffirmed its Buy rating. Raymond James recently set an $86 target and maintained Strong Buy. The analyst activity suggests Wall Street sees substantial upside if RAP-219 succeeds in later-stage development. BTIG Research price target update HC Wainwright rating update
• Positive Sentiment: CFO Troy Ignelzi bought 5,500 shares for $143,550. The purchase increased his direct holdings by 55% to 15,500 shares, a potentially supportive signal of management confidence. SEC insider ownership filing
• Neutral Sentiment: The clinical results move RAP-219 toward Phase 3 but do not eliminate biotechnology risks, including trial execution, regulatory approval, funding needs, and eventual commercialization.
• Negative Sentiment: Some coverage characterized the trial outcome as narrower than investors initially hoped. Rapport also remains unprofitable, recently reporting quarterly EPS below consensus, which could limit gains if future clinical or financial results disappoint. Rapport bipolar data analysis

Institutional Trading of Rapport Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of RAPP. Engineers Gate Manager LP bought a new stake in Rapport Therapeutics during the second quarter valued at about $888,000. Wellington Management Group LLP lifted its position in shares of Rapport Therapeutics by 11.2% in the second quarter. Wellington Management Group LLP now owns 86,988 shares of the company's stock valued at $3,625,000 after acquiring an additional 8,757 shares in the last quarter. Artia Global Partners LP bought a new position in shares of Rapport Therapeutics in the second quarter worth about $5,772,000. Bank of America Corp DE bought a new position in shares of Rapport Therapeutics in the second quarter worth about $3,170,000. Finally, Jupiter Topco LLC purchased a new stake in shares of Rapport Therapeutics during the second quarter worth about $574,000.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on RAPP shares. Wells Fargo & Company lowered their price objective on shares of Rapport Therapeutics from $51.00 to $50.00 and set an "overweight" rating on the stock in a research note on Wednesday. Citigroup restated an "outperform" rating on shares of Rapport Therapeutics in a research report on Tuesday. William Blair initiated coverage on shares of Rapport Therapeutics in a report on Tuesday, July 28th. They set an "outperform" rating for the company. JonesTrading increased their price target on shares of Rapport Therapeutics from $50.00 to $82.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, Leerink Partners initiated coverage on shares of Rapport Therapeutics in a research report on Wednesday, June 24th. They issued an "outperform" rating and a $52.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $68.36.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company's approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport's lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.